Nanoparticle Solutions to Cancer
Our Value Proposition
Nanoparticle-based drug delivery systems suffer from poor accumulation in tumors with traditional "active" or "passive" targeting strategies netting a median delivery efficiency of just 0.7% of the injected dose reaching the tumor.
Our solution to this problem is a novel, patented, expansile nanoparticle that employs a unique Materials-Based Targeting strategy to achieve a 50X improvement in delivery efficiency compared to traditional systems. With this improvement, we demonstrate an increase in survival of over 200% compared to clinical standard of care in ovarian cancer and intraperitoneal mesothelioma.
Treatments for ovarian cancer and intraperitoneal mesothelioma represent a market of ~$250M with additional potential markets in pancreatic, colorectal and other gastric cancers of over $750M.
How it Works
Paclitaxel-loaded expansile nanoparticles, or "PTX-eNPs" for short, localize to intraperitoneal tumors with over 95% accuracy. Once inside a tumor, eNPs swell causing the particle to become stuck whereupon the payload (a drug called paclitaxel) is released, killing the cancer cell.
Pertinent
Publications
April 12, 2017
Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle
This paper summarizes the pre-clinical development of the expansile nanoparticle technology from its inception through mid-late preclinical efficacy and pharmacokinetics studies. In addition to its use as a drug delivery system, several additional applications are described including use as a fluorescent-guide for cytoreductive surgery and as tool for two-step delivery.
June 13, 2016
Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma
This article details the biodistribution, pharmacokinetics and efficacy of paclitaxel-loaded expansile nanoparticles in a murine model of peritoneal mesothelioma.
November 06, 2012
Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma
This paper demonstrates that expansile nanoparticles achieve superior control of tumor growth compared to the clinical standard of care in ovarian cancer.